Journal of Liver Cancer

Sung Bum Cho

3 Articles

Acute Pulmonary Infarction Complicated with Thromboembolism as the First Manifestation of Hepatocellular Carcinoma: Chae June Lim, ji Yun Hong, Chung Hwan Jun, Sung Kyu Choi, Sung Bum Cho; J Liver Cancer. 2017;17(2):163-167. Published online September 30, 2017; DOI: https://doi.org/10.17998/jlc.17.2.163

Abstract PDF: Acute pulmonary infarction by tumoral thromboemboli is an extremely rare fatal complication as the first clinical manifestation of hepatocellular carcinoma (HCC) patient with tumoral thrombi in the inferior vena cava. The treatment method has not been established and shown to very poor prognosis despite of trying various modalities such as anticoagulation, radiotherapy and thromboembolectomy. Here, we describe a 74-year-old man who was diagnosed with HCC that presented as pulmonary thromboembolism and subsequent pulmonary infarction as the first manifestation.

Radioembolization of Unresectable Hepatocellular Carcinoma: Yun Hwan Joseph Kim, Sung Bum Cho, Hwan Hoon Chung; Journal of the Korean Liver Cancer Study Group. 2010;10(1):29-34. Published online June 30, 2010

Abstract PDF: Transarterial radioembolization (TARE) using Yttrium-90 (Y-90) microspheres is emerging as a mainstream treatment modality in the management of patients with primary and metastatic liver cancer. Yttrium-90 is a high energy beta particle emitting radioisotope. The intellectual basis of Y-90 microsphere treatment is the preferential distribution of microspheres, when injected in the hepatic artery, yielding much higher concentrations in the tumor compartment than the normal liver parenchyma. The technique involves the administration of Y-90 microspheres into the hepatic artery accessed via transfemoral route, showing almost similar procedure with transarterial chemoembolization (TACE). The Y-90 microspheres are entrapped within the microvasculature, and release beta radiation. The high tumor to liver concentration ratio results in an effective tumoricidal radiation absorbed dose whilst limiting the radiation injury to the normal liver. With such a therapeutic mechanism of this method, Y-90 microspheres have been used as a treatment modality both for primary HCC and for pre-transplant management of HCC with promising results. But preliminary evidence also suggests that the TACE and TARE provided similar effectiveness and toxicity in patients with unresectable HCC. In conclusion, we think that prospective, randomized controlled trials using current therapies are needed to better define optimal management of unresectable HCC.

Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Arterioportal Shunt : A Report of One Case: Sang Kyun Yu, Soon Ho Um, Cheol Young Kim, Sung Bum Cho, Nam Hee Won; Journal of the Korean Liver Cancer Study Group. 2004;4(1):29-32. Published online June 30, 2004

Abstract PDF: Transcatheter arterial chemoembolization(TACE) is an effective treatment method in the management of patients with inoperable hepatocellular carcinoma. The effectiveness of TACE, however, is decreased, when arterioportal shunt is present, since embolic and chemotherapeutic agents are diverted from the tumor to the normal parenchyma through branches of the portal vein. In such case, TACE may not only be ineffective, but also cause hepatic infarction followed by hepatic failure. We report a case of hepatocellular carcinoma with arterioportal shunt, successfully treated by TACE.